GlassScriptPhysician profile
Chere A Bohr
NPI 1578057196
$746.94
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $548 · 2022: $143 · 2024: $55.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $38.95 · Education: $16.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $38.95 |
| Education | $16.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $132.42 | 2021-2022 | |
| Daiichi Sankyo INC. | $97.58 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $78.73 | 2021 | |
| Merck Sharp & Dohme LLC | $59.94 | 2021 | |
| Viiv Healthcare Company | $41.28 | 2021 | |
| Lilly USA, LLC | $37.81 | 2021 | |
| Alfasigma USA, INC. | $34.56 | 2021 | |
| Abbvie INC. | $30.00 | 2022 | |
| Inari Medical, INC. | $28.72 | 2022 | |
| Dexcom, INC. | $24.97 | 2021 | |
| Calliditas Therapeutics US INC. | $24.59 | 2024 | |
| Sanofi-Aventis U.S. LLC | $24.12 | 2021 | |
| Pfizer INC. | $23.68 | 2021 | |
| Mylan Specialty L.P. | $23.18 | 2021 | |
| Abbott Laboratories | $20.45 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $18.29 | 2021 | |
| Travere Therapeutics, INC. | $16.89 | 2024 | |
| Nestle Healthcare Nutrition INC. | $15.37 | 2021 | |
| Vifor Pharma, INC. | $14.36 | 2024 | Veltassa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chere Bohr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.